CA3233201A1 - Benzimidazole carboxylic acids as glp-1r agonists - Google Patents
Benzimidazole carboxylic acids as glp-1r agonists Download PDFInfo
- Publication number
- CA3233201A1 CA3233201A1 CA3233201A CA3233201A CA3233201A1 CA 3233201 A1 CA3233201 A1 CA 3233201A1 CA 3233201 A CA3233201 A CA 3233201A CA 3233201 A CA3233201 A CA 3233201A CA 3233201 A1 CA3233201 A1 CA 3233201A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- optionally substituted
- alkyl
- ring
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163261717P | 2021-09-27 | 2021-09-27 | |
| US63/261,717 | 2021-09-27 | ||
| PCT/US2022/044915 WO2023049518A1 (en) | 2021-09-27 | 2022-09-27 | Benzimidazole carboxylic acids as glp-1r agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3233201A1 true CA3233201A1 (en) | 2023-03-30 |
Family
ID=83899713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3233201A Pending CA3233201A1 (en) | 2021-09-27 | 2022-09-27 | Benzimidazole carboxylic acids as glp-1r agonists |
Country Status (25)
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| AU2023224854A1 (en) * | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| WO2024051700A1 (zh) * | 2022-09-05 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物 |
| US20240360122A1 (en) * | 2023-03-29 | 2024-10-31 | Terns (Suzhou) Biotechnology Co., Ltd. | Polymorphic forms and salts of a glp-1r agonist |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| WO2024212742A1 (zh) * | 2023-04-10 | 2024-10-17 | 上海研健新药研发有限公司 | 一种glp-1r激动剂，其制备方法和应用 |
| EP4777197A2 (en) | 2023-09-14 | 2026-07-22 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025109387A1 (en) | 2023-11-24 | 2025-05-30 | Ascletis Pharma (China) Co., Limited | Glp-1r agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202600132A (zh) | 2024-03-08 | 2026-01-01 | 美商安尼波那生物公司 | 用於治療肥胖症及提高減重之方法 |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9305623D0 (en) | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
| GB9305641D0 (en) | 1993-03-18 | 1993-05-05 | Merck Sharp & Dohme | Therapeutic agents |
| EP0689535B1 (en) | 1993-03-18 | 1998-09-23 | MERCK SHARP & DOHME LTD. | Benzimidazole derivatives |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| US6960589B2 (en) | 2001-03-09 | 2005-11-01 | Abbott Laboratories | Benzimidazoles that are useful in treating sexual dysfunction |
| JP4637481B2 (ja) | 2001-10-19 | 2011-02-23 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | Ｃｄｓ１／ｃｈｋ２阻害剤および癌治療における化学療法または放射線療法の補助剤としての２−フェニルベンズイミダゾールおよびイミダゾ−［４，５］−ピリジン |
| US20040127504A1 (en) | 2002-09-06 | 2004-07-01 | Cowart Marlon D. | Benzimidazoles that are useful in treating sexual dysfunction |
| CA2523743A1 (en) | 2003-04-30 | 2004-11-18 | The Institutes For Pharmaceutical Discovery, Llc | Heterocycle substituted carboxylic acids as inhibitors of protein tyrosine phosphatase-1b |
| ATE478067T1 (de) | 2006-03-31 | 2010-09-15 | Janssen Pharmaceutica Nv | Benzoimidazol-2-yl pyridine und pyrazine als modulatoren des histamin-h4-rezeptors |
| WO2008012623A1 (en) | 2006-07-25 | 2008-01-31 | Pfizer Products Inc. | Benzimidazolyl compounds as potentiators of mglur2 subtype of glutamate receptor |
| SG174125A1 (en) | 2009-04-02 | 2011-10-28 | Merck Serono Sa | Dihydroorotate dehydrogenase inhibitors |
| EP2414348B1 (en) | 2009-04-03 | 2013-11-20 | Merck Sharp & Dohme Corp. | Bicyclic piperidine and piperazine derivatives as gpcr modulators for the treatment of obesity, diabetes and other metabolic disorders |
| CN103221404B (zh) | 2010-05-13 | 2015-12-16 | 安姆根有限公司 | 可用作pde10抑制剂的不饱和氮杂环化合物 |
| HUE049152T2 (hu) | 2012-07-01 | 2020-09-28 | Novo Nordisk As | Hosszantartó hatású GLP-1 peptidek alkalmazása |
| WO2015166398A1 (en) | 2014-04-30 | 2015-11-05 | Aurigene Discovery Technologies Limited | 3h-imidazo[4,5-b]pyridine derivatives as dihydroorotate dehydrogenase inhibitors |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| WO2018109607A1 (en) | 2016-12-16 | 2018-06-21 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| JP7461104B2 (ja) | 2017-11-29 | 2024-04-03 | 中外製薬株式会社 | Ｇｌｐ－１受容体アゴニスト作用を持つピラゾロピリジン誘導体を含有する医薬組成物 |
| CA3045644C (en) * | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| FI3806855T3 (fi) | 2018-06-15 | 2023-05-04 | Pfizer | Glp-1 -reseptorin agonisteja ja niiden käyttöjä |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| JP7161605B2 (ja) | 2018-08-31 | 2022-10-26 | ファイザー・インク | Ｎａｓｈ／ｎａｆｌｄおよび関連疾患の治療のための組合せ |
| EA202191432A1 (ru) | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| EP3890748A4 (en) | 2018-12-05 | 2022-12-21 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES |
| AU2020256647B2 (en) | 2019-04-12 | 2025-07-31 | Qilu Regor Therapeutics Inc. | GLP-1R agonists and uses thereof |
| TWI751585B (zh) | 2019-06-28 | 2022-01-01 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| WO2021018023A1 (zh) | 2019-08-01 | 2021-02-04 | 济南泰达领创医药技术有限公司 | 小分子glp-1受体调节剂 |
| CR20220178A (es) * | 2019-10-25 | 2022-06-15 | Gilead Sciences Inc | Compuestos moduladores de glp-1r |
| KR20210059584A (ko) | 2019-11-15 | 2021-05-25 | 일동제약(주) | Glp-1 수용체 작용제 및 이의 용도 |
| ES3029360T3 (en) | 2019-11-15 | 2025-06-24 | Ildong Pharmaceutical Co Ltd | Glp-1 receptor agonist and use thereof |
| EP4069686B1 (en) * | 2019-12-02 | 2025-01-22 | Hyundai Pharm Co., Ltd. | Glp-1 receptor agonist |
| CA3163979A1 (en) | 2019-12-10 | 2021-06-17 | Pfizer Inc. | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d] [1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d] imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| SI4097097T1 (sl) | 2020-01-29 | 2025-04-30 | Gilead Sciences, Inc. | Spojine, ki modulirajo glp-1r |
| PT4097099T (pt) | 2020-02-07 | 2024-07-19 | Gasherbrum Bio Inc | Agonistas heterocíclicos de glp-1 |
| CN115697999A (zh) | 2020-02-13 | 2023-02-03 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| MX2022011349A (es) | 2020-03-18 | 2022-11-10 | Lg Chemical Ltd | Agonista del receptor de glp-1, composición farmacéutica que comprende el mismo, y método para preparar el mismo. |
| CN113493447B (zh) | 2020-04-03 | 2024-06-11 | 轩竹(北京)医药科技有限公司 | Glp-1受体激动剂 |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| WO2021219019A1 (en) | 2020-04-29 | 2021-11-04 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| PT4157832T (pt) | 2020-05-27 | 2024-07-30 | Qilu Regor Therapeutics Inc | Formas de sal e cristal de agonistas de glp-1r e utilizações dos mesmos |
| PH12022553313A1 (en) | 2020-06-04 | 2023-04-12 | Hangzhou Sciwind Biosciences Co Ltd | Five-membered heteroaromatic imidazole compound and use thereof |
| CN111548311B (zh) | 2020-06-04 | 2021-04-23 | 山西医科大学 | 一种小分子glp-1r激动剂及其应用 |
| WO2021249492A1 (zh) | 2020-06-10 | 2021-12-16 | 南京明德新药研发有限公司 | 甲基取代的苯并二噁唑类化合物及其应用 |
| TW202214610A (zh) | 2020-06-19 | 2022-04-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | ６－側氧－３，６－二氫吡啶類衍生物、其製備方法及其在醫藥上的應用 |
| WO2021259309A1 (zh) | 2020-06-24 | 2021-12-30 | 广州市恒诺康医药科技有限公司 | Glp-1受体激动剂及其药物组合物和用途 |
| KR20260040657A (ko) | 2020-07-20 | 2026-03-25 | 에코진 인크. | 테트라히드로피라졸로-피라지닐-디히드로이미다졸론 또는 테트라히드로피라졸로-피리디닐-디히드로이미다졸론 화합물 및 그의 사용 방법 |
| TW202214622A (zh) | 2020-08-06 | 2022-04-16 | 大陸商上海齊魯銳格醫藥研發有限公司 | Ｇｌｐ－１ｒ促效劑及其用途 |
| PE20231181A1 (es) | 2020-08-06 | 2023-08-11 | Gasherbrum Bio Inc | Agonistas del glp-1 heterociclicos |
| JP2023538408A (ja) | 2020-08-21 | 2023-09-07 | ターンズ・ファーマシューティカルズ・インコーポレイテッド | Ｇｌｐ－１ｒ作動薬としての化合物 |
| JP2023538949A (ja) | 2020-08-28 | 2023-09-12 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| JP7812052B2 (ja) | 2020-09-01 | 2026-02-09 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| US20230322771A1 (en) | 2020-09-07 | 2023-10-12 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2022052958A1 (en) | 2020-09-10 | 2022-03-17 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN115515956B (zh) | 2020-09-29 | 2024-06-25 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CN116348464B (zh) | 2020-10-12 | 2026-06-16 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| WO2022078380A1 (en) | 2020-10-13 | 2022-04-21 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2023546055A (ja) | 2020-10-13 | 2023-11-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| US12516041B2 (en) | 2020-10-14 | 2026-01-06 | Qilu Regor Therapeutics Inc. | Crystal forms of GLP-1R agonists and uses thereof |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| WO2022111624A1 (zh) | 2020-11-27 | 2022-06-02 | 深圳信立泰药业股份有限公司 | 一种苯并咪唑类衍生物及其制备方法和医药用途 |
| CN114591308B (zh) | 2020-12-03 | 2024-03-08 | 苏州闻泰医药科技有限公司 | 一类glp-1r受体激动剂化合物及其用途 |
| KR20230124956A (ko) | 2020-12-25 | 2023-08-28 | 스촨 하이스코 파마수티컬 씨오., 엘티디 | 5원 고리 유도체 및 이의 의학적 용도 |
| US20240252492A1 (en) | 2021-01-28 | 2024-08-01 | Carmot Therapeutics ,Inc. | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| EP4304711A1 (en) | 2021-03-11 | 2024-01-17 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
| US12180197B2 (en) | 2021-03-11 | 2024-12-31 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
| CN116940561B (zh) | 2021-03-22 | 2026-08-11 | 杭州中美华东制药有限公司 | 噻吩类glp-1受体激动剂及其用途 |
| US20220348564A1 (en) | 2021-03-24 | 2022-11-03 | Eccogene (Shanghai) Co., Ltd. | Phenyl-[1,3]dioxolo[4,5-c]pyridinyl-phenyl-, phenyl-[1,3]dioxolo[4,5-c]pyridinyl-heteroaryl-, or phenyl-(1,3)dioxo[4,5-c]pyridinyl-piperidinyl-methyl-oxetanylmethyl-1h-benzo[d]imidazole-carboxylic acid derivatives and methods of using same |
| EP4317145A4 (en) | 2021-03-24 | 2025-03-12 | Shionogi & Co., Ltd | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
| ES2925124B2 (es) | 2021-03-29 | 2024-04-08 | Fundacion Univ San Antonio | Tratamiento de la obesidad |
| US20240300928A1 (en) | 2021-04-08 | 2024-09-12 | Lg Chem, Ltd. | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| LT4271672T (lt) | 2021-04-21 | 2026-03-10 | Gilead Sciences, Inc. | Karboksibenzimidazolo junginiai, moduliuojantys glp-1r |
| CN117177970A (zh) | 2021-04-30 | 2023-12-05 | 上海翰森生物医药科技有限公司 | 多环类衍生物调节剂、其制备方法和应用 |
| CA3217720A1 (en) | 2021-05-03 | 2022-11-10 | Xiaohui Du | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| TWI843104B (zh) | 2021-05-20 | 2024-05-21 | 美商美國禮來大藥廠 | 類升糖素肽1受體促效劑 |
| MX2023014740A (es) | 2021-06-10 | 2024-03-13 | Antag Therapeutics Aps | Tratamiento de la obesidad y trastornos relacionados con la obesidad. |
| CN117098758A (zh) | 2021-06-24 | 2023-11-21 | 杭州中美华东制药有限公司 | Glp-1受体激动剂及其组合物和用途 |
| US20240382471A1 (en) | 2021-07-21 | 2024-11-21 | Hepagene Therapeutics (HK) Limited | Glucagon-like peptide-1 receptor modulators and uses thereof |
| CN113480534B (zh) | 2021-07-23 | 2022-05-13 | 广州必贝特医药股份有限公司 | 苯并咪唑或氮杂苯并咪唑-6-羧酸类化合物及其应用 |
| US20240360109A1 (en) | 2021-08-04 | 2024-10-31 | Shanghai Hansoh Biomedical Co., Ltd. | Cycloalkene derivative regulator, preparation method therefor, and application thereof |
| US20240366639A1 (en) | 2021-08-12 | 2024-11-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| EP4392137A1 (en) | 2021-08-27 | 2024-07-03 | Versanis Bio, Inc. | Combination therapies |
| KR20240053617A (ko) | 2021-08-30 | 2024-04-24 | 민드랭크 에이아이 리미티드 | Glp1r 작용제로서의 신규 아릴 에테르 치환 헤테로시클릭 화합물 |
| CN117940422A (zh) | 2021-08-31 | 2024-04-26 | 辉瑞大药厂 | 2-[(4-{6-[(4-氰基-2-氟芐基)氧基]吡啶-2-基}哌啶-1-基)甲基]-1-[(2s)-氧杂环丁烷-2-基甲基]-1h-苯并咪唑-6-羧酸，1,3-二羟基-2-(羟甲基)丙-2-胺盐的固体形式 |
| KR20240056719A (ko) | 2021-09-08 | 2024-04-30 | 시오노기 앤드 컴파니, 리미티드 | 항비만 작용이 관여하는 질환의 예방 및 치료용 의약 |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US20250236627A1 (en) | 2021-10-05 | 2025-07-24 | Astrazeneca Ab | Certain octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057429A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4- b]pyrazines as glp-1 receptor modulators |
| WO2023057427A1 (en) | 2021-10-05 | 2023-04-13 | Astrazeneca Ab | Certain 2,5-diazabicyclo[4.2.0]octanes as glp-1 receptor modulators |
| TWI843243B (zh) | 2021-10-22 | 2024-05-21 | 大陸商盛世泰科生物醫藥技術（蘇州）股份有限公司 | 作為glp-1受體激動劑的化合物、包含其的藥物組成物及其用途 |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| JPWO2023106310A1 (cg-RX-API-DMAC10.html) | 2021-12-07 | 2023-06-15 | ||
| CN114280573B (zh) | 2021-12-09 | 2025-09-26 | 上海禾赛科技有限公司 | 激光雷达及其测量目标反射率的方法和系统 |
| US20250066338A1 (en) | 2021-12-16 | 2025-02-27 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| US20250042882A1 (en) | 2021-12-16 | 2025-02-06 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
| CN118434745A (zh) | 2021-12-29 | 2024-08-02 | 西藏海思科制药有限公司 | 一种glp-1激动剂的盐及其晶型和在医药上的应用 |
| WO2023138684A1 (en) | 2022-01-24 | 2023-07-27 | Gasherbrum Bio , Inc. | Heterocyclic glp-1 agonists |
| JP2025506474A (ja) | 2022-02-09 | 2025-03-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| EP4476216A4 (en) | 2022-02-09 | 2025-12-03 | Gasherbrum Bio Inc | GLP-1 HETEROCYCLIC AGONISTS |
| JP2025505198A (ja) | 2022-02-10 | 2025-02-21 | ノバルティス アーゲー | 肥満の治療のためのｇｌｐ１受容体の活性化因子としての２－（（４－（（ｓ）－２－（４－クロロ－２－フルオロフェニル）－２－メチルベンゾ［ｄ］［１，３］ジオキソール－４－イル）ピペリジン－１－イル）メチル）－１－（（（ｓ）－オキセタン－２－イル）メチル）－１ｈ－イミダゾール誘導体 |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| KR20240148000A (ko) | 2022-02-28 | 2024-10-10 | 애슬레티스 바이오사이언스 코., 엘티디. | Glp-1r 조절 화합물 |
| EP4490155A1 (en) | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2025510741A (ja) | 2022-03-21 | 2025-04-15 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| US20250250269A1 (en) | 2022-04-14 | 2025-08-07 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN114716423A (zh) | 2022-05-20 | 2022-07-08 | 中国科学院上海药物研究所 | 5,6-二氢-1,2,4-三嗪类化合物及其作为glp-1受体激动剂的药学用途 |
| CN116574092B (zh) | 2022-05-20 | 2024-08-20 | 成都地奥九泓制药厂 | 苯并咪唑或氮杂苯并咪唑类化合物、其制备方法及其应用 |
| CN120379988A (zh) | 2022-08-24 | 2025-07-25 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| CN119894885A (zh) | 2022-08-30 | 2025-04-25 | 广州市联瑞制药有限公司 | 苯并双环类化合物及其制备方法和应用 |
| WO2024051700A1 (zh) | 2022-09-05 | 2024-03-14 | 德睿智药(苏州)新药研发有限公司 | 作为glp1r激动剂的新型芳基氘代苄醚取代杂环类化合物 |
| CN119907794A (zh) | 2022-09-22 | 2025-04-29 | 盐野义制药株式会社 | 具有glp-1受体激动剂作用的稠环化合物 |
| US20260098031A1 (en) | 2022-09-22 | 2026-04-09 | Shionogi & Co., Ltd. | Monocyclic compound having glp-1 receptor agonist activity |
| WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
| CR20250178A (es) | 2022-11-16 | 2025-06-06 | Lilly Co Eli | Agonistas del receptor del péptido-1 similar al glucagón |
| JP2026501285A (ja) | 2022-12-22 | 2026-01-14 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| CN118344349A (zh) | 2023-01-13 | 2024-07-16 | 中国科学院上海药物研究所 | 用作glp-1受体激动剂的4-烷氧基苯并咪唑-6-羧酸衍生物 |
| US20240360122A1 (en) | 2023-03-29 | 2024-10-31 | Terns (Suzhou) Biotechnology Co., Ltd. | Polymorphic forms and salts of a glp-1r agonist |
| EP4688144A1 (en) | 2023-03-29 | 2026-02-11 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
-
2022
- 2022-09-27 SI SI202230182T patent/SI4408840T1/sl unknown
- 2022-09-27 TW TW111136613A patent/TW202322806A/zh unknown
- 2022-09-27 EP EP22793036.9A patent/EP4408840B1/en active Active
- 2022-09-27 CN CN202280076014.4A patent/CN118251391A/zh active Pending
- 2022-09-27 DK DK22793036.9T patent/DK4408840T3/da active
- 2022-09-27 AU AU2022349020A patent/AU2022349020A1/en active Pending
- 2022-09-27 EP EP24211557.4A patent/EP4537899A3/en not_active Withdrawn
- 2022-09-27 WO PCT/US2022/044915 patent/WO2023049518A1/en not_active Ceased
- 2022-09-27 KR KR1020247014116A patent/KR20240068737A/ko not_active Withdrawn
- 2022-09-27 SM SM20250374T patent/SMT202500374T1/it unknown
- 2022-09-27 PE PE2024000596A patent/PE20241130A1/es unknown
- 2022-09-27 PT PT227930369T patent/PT4408840T/pt unknown
- 2022-09-27 IL IL311667A patent/IL311667A/en unknown
- 2022-09-27 ES ES22793036T patent/ES3049198T3/es active Active
- 2022-09-27 PL PL22793036.9T patent/PL4408840T3/pl unknown
- 2022-09-27 JP JP2024518821A patent/JP2024534621A/ja not_active Withdrawn
- 2022-09-27 LT LTEPPCT/US2022/044915T patent/LT4408840T/lt unknown
- 2022-09-27 HR HRP20251161TT patent/HRP20251161T1/hr unknown
- 2022-09-27 CA CA3233201A patent/CA3233201A1/en active Pending
- 2022-09-27 FI FIEP22793036.9T patent/FI4408840T3/fi active
- 2022-09-27 US US17/954,047 patent/US20230150998A1/en not_active Abandoned
- 2022-09-27 HU HUE22793036A patent/HUE073500T2/hu unknown
- 2022-09-27 MX MX2024003872A patent/MX2024003872A/es unknown
- 2022-09-27 RS RS20250985A patent/RS67271B1/sr unknown
-
2024
- 2024-03-25 CL CL2024000861A patent/CL2024000861A1/es unknown
- 2024-04-22 CO CONC2024/0005060A patent/CO2024005060A2/es unknown
- 2024-11-22 US US18/956,385 patent/US20250282772A1/en active Pending
-
2025
- 2025-01-13 US US19/018,788 patent/US12378238B2/en active Active
- 2025-01-13 US US19/018,754 patent/US12378236B2/en active Active
- 2025-01-13 US US19/018,773 patent/US12378237B2/en active Active
- 2025-01-13 US US19/018,805 patent/US12522596B2/en active Active
- 2025-01-13 US US19/018,817 patent/US12378239B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4408840B1 (en) | Benzimidazole carboxylic acids as glp-1r agonists | |
| US12024507B2 (en) | Compounds as GLP-1R agonists | |
| US12410163B2 (en) | Compounds as GLP-IR agonists | |
| KR101939710B1 (ko) | B형 간염의 항바이러스성 제제 | |
| CA2957898C (en) | Pyrrolopyrimidine derivatives as nr2b nmda receptor antagonists | |
| CA3178647A1 (en) | Substituted tricyclic amides, analogues thereof, and methods using same | |
| HK40115043A (en) | Benzimidazole carboxylic acids as glp-1r agonists | |
| HK40115043B (en) | Benzimidazole carboxylic acids as glp-1r agonists | |
| HK40113150A (en) | Benzimidazole carboxylic acids as glp-1r agonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241112 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241112 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250902 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250902 |